DRG Market Assessment reports

Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder marked by considerable morbidity and mortality. Despite the availability of a wide array of drugs for PAH, substantial…

Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder characterized by high blood pressure in the arteries of the lungs. It is a progressive condition marked by considerable…

Pulmonary hypertension (PH) constitutes a group of rare diseases, including pulmonary arterial hypertension (PAH), yet the commercial potential for novel drugs approved for PH indications is…

Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We…

Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We…

Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We…

Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We…

Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder characterized by high blood pressure in the arteries of the lungs. It is a progressive condition marked by considerable…

PAH is a rare, life-threatening disorder marked by considerable morbidity and mortality. Despite the availability of a wide array of drugs for PAH, substantial unmet need remains for more-…

Pulmonary hypertension (PH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Off-label drug use is widespread because drugs have been approved only for the…

Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder marked by considerable morbidity and mortality. A wide array of drugs are available to treat PAH. Phosphodiesterase 5 (PDE…

Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the disease’s rarity, the potential commercial opportunities for drugs…